Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.46 |
| ▸ | NPC1 | O15118 | 8/20 | 0.46 |
| ▸ | AR | P10275 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.43 |
| ▸ | HPGD | P15428 | 5/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.43 |
| ▸ | PKM | P14618 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4875167 | 0.88 | MAPT (0.46) | RAB9ANPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL3691463 | 0.81 | ALDH1A1 (0.39) | RAB9ANPC1ARCYP3A4CYP1A2 | |
| SCHEMBL29374931 | 0.79 | RAB9A (0.64) | RAB9ANPC1ARCYP3A4CYP1A2 | |
| SCHEMBL170196 | 0.79 | RAB9A (0.64) | RAB9ANPC1ARCYP3A4CYP1A2 | |
| Hydrochloric Acid SCHEMBL31243061 | 0.77 | ALDH1A1 (0.63) | RAB9ANPC1ARCYP3A4CYP1A2 | |
| SCHEMBL10866984 | 0.77 | RAB9A (0.61) | RAB9ANPC1ARCYP3A4CYP1A2 | |
| SCHEMBL31365172 | 0.77 | RAB9A (0.61) | RAB9ANPC1ARCYP3A4CYP1A2 | |
| SCHEMBL34463709 | 0.77 | RAB9A (0.61) | RAB9ANPC1ARCYP3A4CYP1A2 | |
| SCHEMBL31490600 | 0.77 | RAB9A (0.61) | RAB9ANPC1ARCYP3A4CYP1A2 | |
| SCHEMBL30883993 | 0.77 | RAB9A (0.61) | RAB9ANPC1ARCYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015193-A1 | Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2008-01-17 | — | — | US | claimed |
| WO-2007149395-A2 | 2,5-SUBSTITUTED OXAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | AMPHORA DISCOVERY CORPORATION (US) | 2007-12-27 | — | — | WO | claimed |
| US-20080015193-A1 | Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2008-01-17 | — | — | US | disclosed |
| WO-2007149395-A2 | 2,5-SUBSTITUTED OXAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | AMPHORA DISCOVERY CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
| US-6063956-A | APPLYING FUNGICIDE OR INSECTICIDE TO THE LOCUS WHERE CONTROL IS DESIRED | ROHM AND HAAS COMPANY (US) | 2000-05-16 | — | — | US | disclosed |
| US-5366970-A | Cephem compounds and pharmaceutically acceptable salts thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015193-A1 | Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof | ATP5ME, ATP5MG, ATP5MK | RAB9A 3960/4885NPC1 2981/4885AR 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.